Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy by Oehus, Ann-Kathrin et al.








Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate
cancer after radical prostatectomy and salvage radiotherapy
Oehus, Ann-Kathrin ; Kroeze, Stephanie G C ; Schmidt-Hegemann, Nina-Sophie ; Vogel, Marco M E ;
Kirste, Simon ; Becker, Jessica ; Burger, Irene A ; Derlin, Thorsten ; Bartenstein, Peter ; Eiber,
Matthias ; Mix, Michael ; la Fougère, Christian ; Belka, Claus ; Combs, Stephanie E ; Grosu, Anca-Ligia
; Müller, Arndt-Christian ; Guckenberger, Matthias ; Christiansen, Hans ; Henkenberens, Christoph
Abstract: Background: A substantial number of patients will develop further biochemical progression
after radical prostatectomy (RP) and salvage radiotherapy (sRT). Recently published data using prostate-
specific membrane antigen ligand positron emission tomography (PSMA - PET) for re-staging suggest
that those recurrences are often located outside the prostate fossa and most of the patients have a limited
number of metastases, making them amenable to metastasis-directed treatment (MDT). Methods: We
analyzed 78 patients with biochemical progression after RP and sRT from a retrospective European
multicenter database and assessed the biochemical recurrence-free survival (bRFS; PSA < nadir + 0.2
ng/ml or no PSA decline) as well as the androgen deprivation therapy- free survival (ADT-FS) using
Kaplan-Meier curves. Log-rank test and multivariate analysis was performed to determine influencing
factors. Results: A total of 185 PSMA - PET positive metastases were detected and all lesions were
treated with radiotherapy (RT). Concurrent ADT was prescribed in 16.7% (13/78) of patients. The
median PSA level before RT was 1.90 ng/mL (range, 0.1-22.1) and decreased statistically significantly
to a median PSA nadir level of 0.26 ng/mL (range, 0.0-12.25; p < 0.001). The median PSA level of 0.88
ng/mL (range, 0.0-25.8) at the last follow-up was also statistically significantly lower (p = 0.008) than
the median PSA level of 1.9 ng/mL (range, 0.1-22.1) before RT. The median bRFS was 17.0 months (95%
CI, 14.2-19.8). After 12 months, 55.3% of patients were free of biochemical progression. Multivariate
analyses showed that concurrent ADT was the most important independent factor for bRFS (p = 0.01).
The median ADT-FS was not reached and exploratory statistical analyses estimated a median ADT-FS of
34.0 months (95% CI, 16.3-51.7). Multivariate analyses revealed no significant parameters for ADT-FS.
Conclusions: RT as MDT based on PSMA - PET of all metastases of recurrent prostate cancer after RP
and sRT represents a viable treatment option for well-informed and well-selected patients. Keywords:
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Abstract
Background: A substantial number of patients will develop further biochemical progression after radical
prostatectomy (RP) and salvage radiotherapy (sRT). Recently published data using prostate-specific membrane
antigen ligand positron emission tomography (PSMA - PET) for re-staging suggest that those recurrences are often
located outside the prostate fossa and most of the patients have a limited number of metastases, making them
amenable to metastasis-directed treatment (MDT).
Methods: We analyzed 78 patients with biochemical progression after RP and sRT from a retrospective European
multicenter database and assessed the biochemical recurrence-free survival (bRFS; PSA < nadir + 0.2 ng/ml or no
PSA decline) as well as the androgen deprivation therapy- free survival (ADT-FS) using Kaplan-Meier curves. Log-
rank test and multivariate analysis was performed to determine influencing factors.
Results: A total of 185 PSMA – PET positive metastases were detected and all lesions were treated with
radiotherapy (RT). Concurrent ADT was prescribed in 16.7% (13/78) of patients. The median PSA level before RT was
1.90 ng/mL (range, 0.1–22.1) and decreased statistically significantly to a median PSA nadir level of 0.26 ng/mL
(range, 0.0–12.25; p < 0.001). The median PSA level of 0.88 ng/mL (range, 0.0–25.8) at the last follow-up was also
statistically significantly lower (p = 0.008) than the median PSA level of 1.9 ng/mL (range, 0.1–22.1) before RT. The
median bRFS was 17.0 months (95% CI, 14.2–19.8). After 12 months, 55.3% of patients were free of biochemical
progression. Multivariate analyses showed that concurrent ADT was the most important independent factor for
bRFS (p = 0.01). The median ADT-FS was not reached and exploratory statistical analyses estimated a median ADT-
FS of 34.0 months (95% CI, 16.3–51.7). Multivariate analyses revealed no significant parameters for ADT-FS.
Conclusions: RT as MDT based on PSMA - PET of all metastases of recurrent prostate cancer after RP and sRT
represents a viable treatment option for well-informed and well-selected patients.
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Background
Salvage radiotherapy (sRT) represents the standard of
care for patients with a biochemical relapse after radical
prostatectomy (RP) of localized prostate cancer (PCa)
[1]. Nevertheless, a substantial number of patients will
not benefit permanently from sRT and will develop bio-
chemical progression [2, 3]. Recently published data sug-
gest that early recurrences are often located outside the
prostate fossa [4–6], and a large proportion of these pa-
tients (40–70%) have a limited number of metastases,
making them amenable to metastasis-directed treatment
(MDT) [7]. These cases are usually considered oligorecur-
rent disease. Despite the lack of a biologically defined oli-
gometastatic status and a strict clinical definition, the
evidence for MDT for patients with a generally accepted
imaging-based cut-off of five metastases - outside large
randomized prospective trials - is consistently increasing
[8, 9]. Recent data showed a positive effect on the clinical
outcome for MDT with low toxicity, although staging with
positron emission tomography (PET) with prostate-
specific membrane antigen (PSMA) radio ligands was not
available and the number of metastases could therefore be
underestimated [10, 11].
Furthermore, the successful implementation of PSMA
-PET – outperforming all other imaging modalities [12] –
significantly improves patient selection for MDT and sub-
sequently leads to high acceptance of MDT in patients
with limited prostate cancer recurrence [13]. PSMA - PET
allows individualizing treatment concepts that aim to im-
prove PSA progression-free survival, defer the initiation of
androgen deprivation therapy ADT and potentially cure
the patient [14]. In addition, the optimal timing of initi-
ation of ADT for asymptomatic biochemically progressive
disease after RP and sRT remains unknown [1]. Import-
antly, it has been shown that ADT could be safely deferred
in a relevant proportion of patients by MDT, which may
also improve quality of life (QoL) [8, 9].
However, the potential usefulness of a PSMA - PET-
guided MDT approach in the clinical setting even after
sRT (i.e., in patients with a longer treatment history than
in previously investigated approaches) is underexplored.
Therefore, we investigated the efficacy and safety of de-
finitive radiotherapy (RT) for PSMA - PET-detected oli-
gometastatic disease after both RP and prior sRT in a
retrospective European multicenter study.
Methods
This retrospective multicenter study was approved by
the institutional review boards of all participating centers
(BASEC-Nr. 2017–01499). Included patients (n = 379)
were treated with definitive PSMA - PET-based RT as
MDT between 04/2013 and 01/2018 in 6 academic cen-
ters in Switzerland and Germany. In the present analysis,
we included 78 patients with biochemical progression
after initial RP plus sRT and subsequent diagnosis of oli-
gorecurrent PCa on the basis of PSMA - PET. All pa-
tients presented with no evidence of distant metastases
(M0) at initial diagnosis and salvange radiotherapy of the
prostatic bed. PCa recurrence was defined as nodal or
extranodal metastases (N1 or M1a/1b/1c) in PSMA -
PET. PET-CT or PET-MRI was performed with 68Ga
radiolabelled PSMA- ligand. Any PSA level at the time
of RT was accepted. Oligorecurrent disease was defined
as ≤5 visceral or bone metastases; there was no limit on
lymph node metastases. All cases were discussed and ap-
proved for RT by the local multidisciplinary uro-
oncologic boards. The patients’ characteristics are sum-
marized in Table 1.
PET imaging
Each patient received PET imaging with a 68Ga-labeled
PSMA ligand [15], and imaging was performed according to
the joint EANM and SNMMI guidelines [16]. PSMA - PET
scans were acquired in conjunction with either contrast-
enhanced or low-dose computed tomography (PET/CT;
87.2%, 68/78) or magnetic resonance imaging (PET/MRI;
12.8%, 10/78). Visual assessment of focally increased tracer
uptake higher than the surrounding background activity
was used as the criterion for malignancy [8].
Radiotherapy treatment
Patients were treated with stereotactic body radiation
therapy (SBRT) or with conventionally fractionated RT
(CF-RT), including either a conventionally fractionated
simultaneously integrated boost (SIB) or a sequential
SBRT boost to the PET-positive lesion. Definitive RT
was delivered to all PSMA ligand-positive lesions. Irradi-
ation was performed at the discretion of the participat-
ing center in terms of radiation dose, elective nodal
volumes, and type and length of concurrent ADT. The
prescribed radiotherapy dose was converted to EQD2 in
Gy using an α/β ratio of 1.5 [17].
Follow-up and endpoints
Biochemical recurrence-free survival (bRFS) was mea-
sured from the last day of RT to the diagnosis of bio-
chemical recurrence and defined according to PSA
failure after RP [18]: PSA ≥ 0.2 ng/ml above the PSA
nadir following RT. When serum PSA did not respond
to RT, the pre-RT level with an increase of ≥0.2 ng/ml
was defined as bRFS. Follow-up was performed accord-
ing to institutional protocols, with regular serum PSA
measurements and clinical follow-up visits. Secondary
outcomes were ADT-free survival (ADT-FS), overall sur-
vival (OS) and toxicity. The timing of imaging at bio-
chemical recurrence after RT, as well as the initiation of
local and/or systemic therapies, was at the discretion of
the local multidisciplinary uro-oncologic board. RT-
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associated toxicity was analyzed using the National Can-
cer Institute Common Terminology Criteria for Adverse
Events (CTCAE) v4.0 [19].
Statistical analysis
For statistical analysis, SPSS Statistics v25.0 (IBM,
Armonk, New York, USA) was used. We used the paired
Student’s t test to compare pre-RT with post-RT para-
metric parameters and the Wilcoxon signed-rank test
when data were not normally distributed. The time to
event data was calculated using the Kaplan-Meier
method. Established factors for treatment failure after
sRT [20, 21] were analyzed with log rank test in univari-
ate analyses, and significant factors were further assessed
with multivariate analyses to identify independent vari-
ables for bRFS and ADT-FS. P-values of < 0.05 were
considered statistically significant.
Results
Result of PSMA ligand PET staging and therapy of
metastases
A total of 185 PSMA ligand positive metastases were de-
tected and treated with RT: 41.6% (77/185) were pelvic
lymph node metastases, 27.6% (51/185) were periaortic
lymph node metastases, 24.3% (45/185) were bone me-
tastases, and 6.5% (12/185) were visceral metastases. A
total of 58.8% of patients (46/78) had only lymph node
metastases, 32.1% (25/78) of patients had only bone me-
tastases, 3.8% (3/78) of patients had lymph node and
bone metastases, 2.6% (2/78) of patients had visceral me-
tastases only, and 2.6% (2/78) of patients had visceral
and lymph node metastases.
Concurrent ADT was prescribed in 16.7% (13/78) of
patients and ADT was deferred in the remaining pa-
tients. Furthermore, additive chemotherapy with doce-
taxel was administered in 30.8% (4/13) of patients with
concurrent ADT. The majority of the patients (57.7%;
45/78) received CF-RT, 20.5% (16/78) received SBRT,
12.8% (10/78) received CF-RT with SBRT boost, and 9%
(7/78) of the patients were treated with CF-RT and a
simultaneous integrated boost (SIB).
Table 2 summarizes the results of the PSMA ligand
PET results and therapy of the metastases.
Patients’ outcome
The median follow-up was 16months (3–54). Overall sur-
vival (OS) was 97.4% after 2 years; 2 patients died of pro-
gressive metastatic PCa. The median PSA level before RT
was 1.90 ng/mL (range, 0.1–22.1) and decreased statisti-
cally significantly to a median PSA nadir level of 0.26 ng/
mL (range, 0.0–12.25; p < 0.001). The median PSA level of
0.88 ng/mL (range, 0.0–25.8) at the last follow-up was also
statistically significantly lower (p = 0.008) than the median
PSA level of 1.9 ng/mL (range, 0.1–22.1) before RT. More-
over, 20.5% (16/78) of all patients had a PSA level < 0.07
ng/mL at the last available follow-up. Nine of these 16 pa-
tients (56.3%) were ADT naïve.
Table 1 Patient characteristics
Age at PCa diagnosis Median (range)
64 (48–78)





Initial N stage n (%)
N0 62 (79,5)
N1 16 (20,5)
Surgical margins n (%)
R0 48 (61,5)
R1 30 (38,5)
Initial risk group n (%)
Intermediate 3 (3.9)
High 29 (37.2)
Very high 46 (58.8)
Initial PSA (ng/ml) Median (range)
11.4 (2.8–231.0)
First PSA after RP (ng/ml) Median (range)
0.07 (0.0–1.9)
Interval in months from RP to sRT Median (range)
11.16 (3.1–172.6)
PSA nadir after sRT (ng/ml) Median (range)
0.84 (0.0–12.2)
Interval in months from sRT to PSA recurrence Median (range)
22.7 (3.0–136.6)
Biochemical non-response after sRT n (%)
4 (5.1)
PSA level at PSMA-PET imaging (ng/ml) Median (range)
1.9 (0.1–22.1)
Patients with ADT at PSMA-ligand PET imaging n (%)
3 (3.9)
PSA-dt at time of PSMA-PET imaging (months) n (%)
< 3 (n) 3 (3.9)
3–6 (n) 32 (41.0)
> 6–12 (n) 23 (29.5)
> 12 (n) 16 (20.5)
unknown 4 (5.1)
ADT androgen deprivation therapy, dt doubling time, PCa prostate cancer,
PSMA-PET prostate-specific membrane antigen positron emission tomography,
PSA prostate-specific antigen, RP radical prostatectomy, sRT
salvage radiotherapy
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A total of 57.7% (42/78) of patients were classified as
having biochemically progressive disease after RT. The
median PSA level at biochemical progression was 0.37
ng/mL (range, 0.1–3.6). The median bRFS was 17.0
months (95% CI, 14.2–19.8; Fig. 1). After 12 months,
55.3% of patients were free of biochemical progression.
Multivariate analyses showed that concurrent ADT was
the most important independent factor for bRFS (p =
0.01). The detailed results of the statistical analyses are
shown in Table 3. Furthermore, 83.3% (35/42) of pa-
tients with biochemically progressive disease underwent
restaging, which was performed with the exception of
one patient (2.9%) with PSMA - PET. The staging re-
vealed new metastases in 85.7% (30/35) of patients and
in 14.3% (5/35) of patients PSMA – PET detected no
metastases. The resulting treatment concepts for pa-
tients with biochemical progression were as follows: in
50% (21/42) of patients, ADT was initiated, and 14.3%
(6/42) of patients started observation with regular PSA
measurements, and in 9.5% (4/42) of patients, repeated
RT was performed. Furthermore, 9.5% (4/42) of patients
received ADT plus repeated RT; 7.1% (3/42) of patients
received taxane-based chemotherapy, and 2.4% (1/42) of
patients received taxane-based chemotherapy plus ADT.
Additionally, in 4.8% (2/42), a therapy with radium-223
dichloride was initiated, and 2.4% (1/42) of patients re-
ceived a secondary hormonal ablation with
enzalutamide.
For ADT-FS analyses, patients among ADT at time of
RT (3.9%; 3/78) or patients who received concurrent
ADT +/− docetaxel (16.7%; 13/78) for RT were ex-
cluded. The median ADT-FS was not reached because
less than half of the patients (38.7%; 24/62) were in need
of ADT at their last follow-up visit. Exploratory statis-
tical analyses estimated a median ADT-FS of 34.0
months (95% CI, 16.3–51.7, Fig. 2). None of the signifi-
cant parameters of the univariate analyses reached sig-
nificance in multivariate analyses. The detailed results of
the statistical analyses are shown in Table 4.
Toxicity
Acute grade III toxicity was not observed; 1.3% (1/78) of
patients developed acute genitourinary toxicity grade II.
Acute gastrointestinal toxicity grade II occurred in 1.3%
(1/78) of patients, and acute gastrointestinal toxicity
grade I occurred in 1.3% (1/78) of patients. Late grade
III gastrointestinal toxicity occurred in 1.3% (1/78) of pa-
tients, and grade II genitourinary toxicity in 1.3% (1/78)
of patients.
Discussion
The implementation of PSMA ligand imaging has sub-
stantially improved the diagnostic accuracy for the detec-
tion of (oligo) metastatic PCa at low PSA levels [5, 22],
leading to the recent guidelines by the European
Organization for Research and Treatment of Cancer
(EORTC) demanding modern imaging methods for trials
investigating MDT in oligometastatic PCa [23]. Although
large randomized prospective studies are lacking, approxi-
mately two-thirds of the experts at the 2017 Advanced
Prostate Cancer Consensus Conference considered MDT
Table 2 PSMA-ligand PET results and radiotherapy of
metastases
PSMA-ligand PET results N (%)
Number of PSMA-ligand positive lesions 185 (100
Total number of LNs 128 (69.2)
Iliac LNs 67 (36.2)
Obturator LNs 6 (3.2)
Perirectal LNs 4 (2.2)
Periaortic/interaortocaval LNs 51 (27.6)
Total number of bone metastases 45 (24.3)
Pelvic bone 24 (13.0)
Spinal bone 10 (5.4)
Other 11 (5.9)
Number of visceral metastases 12 (6.5)
Concurrent ADT at radiotherapy 13 (16.7)
Radiotherapy of metastases N (%)
Radiotherapy of LNs 128 (100)
CF-RT 95 (74.2)
SBRT 5 (3.9)
CF-RT plus SBRT 15 (11.7)
CF-RT with SIB 13 (10.2)
Median dose, EQD2/1.5 Gy (range) 50.9 (50.0–76.1)
N (%)
Radiotherapy of bone metastases 45 (100%)
CF-RT 26 (57.8)
SBRT 15 (33.3)
CF-RT plus SBRT 0 (0)
CF-RT with SIB 4 (8.9)
Median dose, EQD2/1.5 Gy (range) 51.4 (46.4–108.8
N (%)
Radiotherapy of visceral metastases 12 (100)
CF-RT 8 (66.7)
SBRT 4 (33.3)
CF-RT plus SBRT 0
CF-RT with SIB 0
Median dose, EQD2/1.5 Gy (range) 64.7 (57.8–85.0)
ADT androgen deprivation therapy, CF-RT conventionally fractionated
radiotherapy type, Gy Gray, LNs lymph node metastases, PCa prostate cancer,
PSMA-PET prostate-specific membrane antigen positron emission tomography,
PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage
radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous
integrated boost
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as a treatment option for patients with oligorecurrent PCa
[13].
A substantial number of patients will develop further
biochemical progression after sRT [2, 3], and contro-
versy still exists about the optimal timing of initiation of
palliative ADT regarding asymptomatic metastatic pa-
tients because of the lack of prospective trials from the
PSA era [1]. Furthermore, ADT alone offers no curative
potential [1] and significantly impairs QoL in a relevant
number of patients [24]. Therefore, MDT to all detect-
able lesions might shift the treatment concept from pal-
liative to potentially curable [10]. Smaller prospective
trials with heterogeneous patient collectives, one with
choline PET imaging [10], one with PSMA ligand PET
imaging [25] and one with sodium fluoride (NA-F) PET
imaging [11], showed encouraging results for MDT for
oligometastatic prostate cancer.
To the authors’ best knowledge, the assessed subset
from a large retrospective multicenter database including
only patients with oligometastatic disease after RP and
sRT treated with PSMA ligand guided RT is the first
analysis that showed a significant improvement of the
PSA levels. The median PSA levels at the last follow-up
visit were significantly lower than the PSA levels prior to
RT (1.90 vs. 0.88; p = 0.008). Furthermore, a significant
number of patients receiving RT alone could be spared
Fig. 1 Kaplan-Meier curves of biochemical recurrence-free survival (bRFS) after 68 Ga-labeled PSMA ligand PET directed radiotherapy of prostate
cancer (a) with or without ADT (p = 0.03; b)
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ADT treatment for an estimated median time of 34
months. Our results are better than the results of the
STOMP trial, which showed a median ADT-FS of
13.0 months. However, for the STOMP trial, the me-
dian PSA was 5.3 ng/ml, and PSMA ligand imaging
was not available, thereby decreasing the likelihood of
identifying a truly oligometastatic cohort of patients
[10]. The POPSTAR trial reported a 2-year ADT-FS
of 48%, which is slightly worse than the results we
observed, possibly due to a higher proportion of pa-
tients with bone metastases. Furthermore, imaging
was performed with Na-F PET. Na-F PET imaging
outperforms conventional imaging for bone metasta-
ses but cannot depict nodal metastases, increasing
the likelihood of including patients with bone metas-
tases but underestimating lymph node metastases,
possibly leading to a patient cohort with unfavorable
prognosis [11].
Table 3 Results of uni- and multivariate analyses for biochemical progression-free survival (bRFS)
Univariate analysis Multivariable analysis
p value p value OR, (95% CI)
Initial T stage (≤T2 vs ≥ T3) 0.02 0.50 1.43 (0.50–4.11)
Initial N stage (N0 vs N1) 0.07 0.07 3.75 (0.89–15.81)
Initial PSA level in ng/ml (≤20 vs > 20) 0.36
PSA nadir after RP (≤0.07 ng/mL vs > 0,07 ng/mL) 0.04 0.14 2.24 (0.78–6.45)
Number of removed LN at RP (≤15 vs > 15) 0.32
Initial Risk Group (intermediate+high risk vs. very high risk) 0.15
PSA doubling time (≤6 months, > 6 months) 0.46
Radiotherapy type (CF-RT vs. SBRT) 0.11
No. of irradiated metastases (1 vs > 1) 0.37
Type of metastases (lymph node vs bone) 0.18
Concurrent ADT (yes vs no) 0.03 0.01 7.86 (1.51–40.79)
RT-Dose (≤50 Gy vs > 50 Gy) 0.74
ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, dt doubling time, Gy Gray, LN lymph nodes, PSA prostate-specific antigen,
RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost
Fig. 2 Kaplan-Meier curves of androgen deprivation therapy-free survival (ADT-FS) after 68Ga-labeled PSMA PET-directed radiotherapy
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The administration of concurrent ADT in this situ-
ation is currently unknown. RT with concurrent ADT
might improve bRFS and OS for patients with low vol-
ume disease according to the CHAARTED criteria as ex-
trapolated from the Stampede trial [26], although the
study only included patients treated with slightly hypo-
fractionated RT of the prostate. Furthermore, the study
protocol provided no local therapies to asymptomatic
metastases. On the other hand, the STOMP [10] and
POPSTAR trials [11], as well as the data published by
Kneebone et al. [25], demonstrated that MDT alone
might delay ADT for a relevant period. However, pa-
tients with MDT alone develop biochemical progression
earlier than patients with MDT plus ADT. The impact
on OS of MDT alone remains unknown due to the short
follow-up and small sample sizes in the few prospective
trials [10, 11, 25]. There might be concern that patients
who do not respond well to MDT might develop wide-
spread metastases with unfavorable prognoses. On the
other hand, approximately half of the patients will de-
velop oligoprogressive disease after MDT [10], making
these patients amenable to repeated MDT [27]. Fur-
thermore, the presented cohort had PSMA ligand im-
aging for staging purposes, and fewer metastases
should be missed compared to conventional imaging
and choline PET [4, 5, 22], indicating well-selected
patients. Moreover, no data about the biological evo-
lution of prostate cancer are available in the context
of prior local therapies such as RP and sRT. Explora-
tory analyses for patients with metachronous metasta-
ses after initial curative local therapy revealed no OS
benefit for escalated systemic therapy using either the
combination of ADT + docetaxel [28, 29] or ADT +
enzalutamide [30] compared to ADT alone, indicating
a different biology.
We did not find a statistically significant predictor for
ADT-FS in multivariate analyses, such as location (bone
vs. lymph node) or number of metastases. Neither Ost
et al. [10] nor Kneebone et al. [25] identified any clinical
parameter significantly associated with prolonged ADT-
FS, likely because the number of enrolled patients (62
and 57, respectively) was too small for sufficient statis-
tical subgroup analyses. Nevertheless, a recently pub-
lished SEER database analysis suggested that patients
with M1a tumor stage have a significantly greater clin-
ical benefit from local therapies to the prostate than pa-
tients with M1b tumor stage [31]. Additionally some
patients presented with progression among ADT at
PSMA ligand staging and must be considered as early
castration-resistant. Data about RT as MDT on this
oncological situation are rare, although Berghen et al. re-
cently yielded first information that RT substantially
postponed next-line systemic treatment [32]. In general
the definition of oligometastases for prostate cancer is
controversial and there is no general agreement between
different experts panels [13, 33]. The hypothesis generat-
ing phase II STOMP trial included patients up to three
nodal or bone metastases based upon Choline PET sta-
ging [10], whereas the expert panel of the APCCC 2017
did not reach consensus regarding a numerical definition
of oligometastasis, and 61% of the panelists voted for a
limited number of bone and/or lymph nodes metastases
that influences treatment decisions [13]. The expert panel
of the Italian Association of Radiotherapy and Clincial On-
cology (AIRO) reached a consensus of 100% for metachro-
nous oligometastatic castration-sensitive prostate cancer
with primary tumor controlled and up to three metastases
(node or bone) [33]. Particularly in comparison to the lat-
ter results of the AIRO expert panel, we used a broader
definition of oligometastases and included patients with a
Table 4 Results of uni- and multivariate analyses for androgen deprivation therapy-free survival (ADT-FS)
Univariate analysis Multivariable analysis
p value p value OR, (95% CI)
Initial T stage (≤T2 vs ≥ T3) 0.07
Initial N stage (N0 vs N1) 0.95
Initial PSA level in ng/ml (≤20 vs > 20) 0.26
PSA nadir after RP (≤0.07 ng/mL vs > 0,07 ng/mL) 0.05 0.20 2.02 (0.68–5.99)
Number of removed LN at RP (≤15 vs > 15) 0.31
Initial risk group (intermediate+high risk vs. very high risk) 0.02 0.10 2.58 (0.8–7.98)
PSA dt (≤6 months, > 6 months) 0.10
Radiotherapy type (CF-RT vs., SBRT) 0.73
No. of irradiated metastases (1 vs > 1) 0.51
Type of metastases (Lymph node vs bone) 0.12
RT dose (≤50 Gy vs > 50 Gy) 0.44
ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, dt doubling time, Gy Gray, LN lymph nodes, PSA prostate-specific antigen,
RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost
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more advanced cancer burden. Furthermore, we there was
no limit on lymph node metastases. Therefore, we cannot
rule out that some patients had little benefit due to our
definition of oligometastatic PCa. On the other hand the
observed clinical outcomes are promising and prospective
trials using PSMA ligand staging will have to investigate
that.
The retrospective nature has inherent limitations and
might have introduced selection bias. Furthermore, the
median follow-up of 16 months and the sample size of
78 patients limited the statistical power, although the
observed clinical results are robust and contribute sig-
nificantly to the discussion of PSMA ligand guided
MDT after RP and sRT in a quickly changing clinical
field. In addition, the study included a selected cohort
with mainly high-risk patients. Therefore, caution should
be taken when generalizing the observed results for pa-
tients with intermediate- or low-risk PCa. Because we
used clinical real-life data from an observational study,
the RT treatment was heterogeneous regarding radio-
therapy dose and field size, as well as the use of concur-
rent ADT. Prospective trials investigating the addition of
ADT, the size of RT fields and the radiotherapy dose are
warranted objectives in the field of relapsed PCa after
RP and sRT at this time.
Conclusion
Even in a clinical setting after both RP and prior sRT,
PSMA - PET-based RT for recurrent PCa with limited
tumor burden was effective and safe. RT alone delayed
the initiation of ADT longer than in other cohorts. RT
of all lesions after RP and sRT based on PSMA - PET
represents a viable treatment option for well-informed
and well-selected patients, including a close follow-up
schedule, particularly after RT alone.
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